A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo

J Exp Med. 1993 Feb 1;177(2):561-6. doi: 10.1084/jem.177.2.561.


Using an in vivo test system, the role of the beta 1 integrin very late activation antigen-4 (VLA-4) in eosinophil accumulation in allergic and nonallergic inflammatory reactions was investigated. Eosinophil infiltration and edema formation were measured as the local accumulation of intravenously injected 111In-labeled eosinophils and 125I-human serum albumin. The inflammatory reactions investigated were a passive cutaneous anaphylaxis (PCA) reaction and responses elicited by intradermal soluble inflammatory mediators (platelet-activating factor, leukotriene B4, C5a des Arg), arachidonic acid, and zymosan particles. The in vitro pretreatment of 111In-eosinophils with the anti-VLA-4 monoclonal antibody (mAb) HP1/2, which crossreacts with guinea pig eosinophils, suppressed eosinophil accumulation in all the inflammatory reactions investigated. Eosinophil accumulation was inhibited to the same extent when mAb HP1/2 was administered intravenously. It is interesting that HP1/2 had no effect on stimulated edema formation. These results suggest a role for VLA-4 in eosinophil accumulation in vivo and indicate a dissociation between the inflammatory events of eosinophil accumulation and edema formation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Edema / immunology
  • Eosinophils / immunology*
  • Guinea Pigs
  • Inflammation / immunology
  • Leukotriene B4 / pharmacology
  • Passive Cutaneous Anaphylaxis
  • Platelet Activating Factor / pharmacology
  • Receptors, Very Late Antigen / immunology*
  • Zymosan / pharmacology


  • Antibodies, Monoclonal
  • Platelet Activating Factor
  • Receptors, Very Late Antigen
  • Leukotriene B4
  • Zymosan